Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

NCT06696417

Status	RECRUITING
Sponsor	First Hospital of China Medical University
Enrollment	1,516 participants

Key Eligibility Criteria

Inclusion (4)

- Age e18 years old at the time of signing the informed consent, regardless of gender;
- Moderate to severe plaque psoriasis was diagnosed;
- Plan to receive vunakizumab therapy as assessed by the investigator;
- The subject voluntarily signs informed consent before the start of any procedures related to the study, can communicate with the researcher smoothly, understands and is willing to strictly comply with the requirements of this clinical study protocol to complete the study; Patients voluntarily sign informed consent forms.

Exclusion (5)

- Previous treatment with biological agents: including but not limited to anti-tumor necrosis factor-±Ţ(NF-±)ą anti-IL-17, anti-IL-17 receptor, anti-IL-12 /IL-23 or IL-23p19 antibody drugs;
- Severe hypersensitivity to vunakizumab active ingredient or any excipients;
- Patients with clinically important active diseases, such as active tuberculosis, active hepatitis, and active malignant tumors;
- Fertile women (defined as all women with physical conditions necessary for pregnancy) and men who are pregnant or unwilling or unable to use highly effective birth control during the study period and within 20 weeks after last receiving the study drug;
- Any other circumstances that the investigator believes will prevent the subject from following and completing the study protocol.

Locations (1 total)

The First Hospital of China Medical University, Shenyang, Liaoning, China